Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing ...

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 ...

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment with a combination of immunotherapy and what has been described in a news ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction ...

I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...